HALOBETASOL PROPIONATE AND TAZAROTENE
Clinical safety rating: avoid
Animal studies have demonstrated safety
Halobetasol propionate is a high-potency corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects via binding to glucocorticoid receptors and modulating gene expression. Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) to regulate gene expression involved in cell proliferation and differentiation.
| Metabolism | Halobetasol propionate is metabolized primarily in the liver via ester hydrolysis and reduction. Tazarotene is metabolized by ester hydrolysis to its active metabolite tazarotenic acid, which is further metabolized via oxidation and conjugation; tazarotenic acid is also metabolized by CYP2C8 and CYP3A4. |
| Excretion | Topical application: Minimal systemic absorption; absorbed drug is primarily metabolized hepatically and excreted renally (tazarotenic acid) and via feces. For halobetasol propionate, renal excretion of metabolites accounts for ~80% and fecal ~20%. For tazarotene, renal excretion of metabolites accounts for ~60% and fecal ~40% after oral administration, but topical absorption is <1%. |
| Half-life | Halobetasol propionate: terminal half-life approximately 5.6 hours after topical application. Tazarotene: terminal half-life of tazarotenic acid is 7–12 hours in plasma after topical application. Clinical context: twice-daily dosing maintains efficacy. |
| Protein binding | Halobetasol propionate: >99% bound to plasma proteins (albumin and corticosteroid-binding globulin). Tazarotene: >99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Halobetasol propionate: not well characterized due to topical route; systemic absorption minimal. Tazarotene: oral Vd ~0.5 L/kg (based on tazarotenic acid); component reflects distribution into tissues. |
| Bioavailability | Topical: Systemic bioavailability is less than 1% for both halobetasol propionate and tazarotene when applied to intact skin. Percutaneous absorption may increase with occlusive dressings, damaged skin, or prolonged use. |
| Onset of Action | Topical: Clinical improvement (reduction in plaque elevation, scaling, erythema) may be observed within 2 weeks of twice-daily application. |
| Duration of Action | Topical: Duration of action supports twice-daily application. After discontinuation, therapeutic effect may persist for several days to weeks, but continuous use is recommended for full clearance. |
Apply a thin layer to affected areas once daily for up to 8 weeks; maximum 60 g per week.
| Dosage form | LOTION |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment; severe impairment (GFR <30 mL/min) not studied. |
| Liver impairment | Contraindicated in patients with hepatic impairment (Child-Pugh class B or C) due to increased systemic exposure. |
| Pediatric use | Not recommended for use in pediatric patients due to risk of HPA axis suppression and other adverse effects. |
| Geriatric use | Use with caution; consider lower starting dose (e.g., apply to smaller areas) due to increased risk of cutaneous and systemic effects from impaired skin barrier or renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Highly teratogenic females must use effective contraception.
| Breastfeeding | Excretion into human milk unknown for both components. Halobetasol propionate may be excreted; tazarotene may enter milk. Risk to infant cannot be excluded. Use caution; avoid application to breast area. M/P ratio not available. |
| Teratogenic Risk | FDA Pregnancy Category X. Tazarotene is a retinoid known to cause fetal harm. Halobetasol propionate is a high-potency corticosteroid. Avoid use in pregnant women. In first trimester, high risk of teratogenicity. Second and third trimesters: risk of fetal growth restriction and adrenal suppression. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Application site reactions burning irritation itching and redness |
| Serious Effects |
["Hypersensitivity to halobetasol propionate, tazarotene, or any component of the formulation.","Pregnancy (due to tazarotene being a retinoid with teratogenic effects; contraindicated in pregnant women or women planning pregnancy)."]
| Precautions | ["Avoid use on face, axillae, or skin folds due to increased risk of local adverse effects and skin atrophy.","Risk of systemic absorption, especially with use over large areas, occlusive dressings, or prolonged use; may cause reversible HPA axis suppression.","Discontinue if skin irritation or contact dermatitis occurs.","Photosensitivity: patients should minimize sun exposure and use sun protection.","Not recommended for use on eroded or infected skin.","Avoid concurrent use of other corticosteroids or retinoids on same treatment area."] |
Loading safety data…
| Fetal Monitoring |
| Monitor fetal growth via ultrasound if inadvertent use. Assess for signs of maternal adrenal suppression (e.g., fatigue, hypotension). Monitor for fetal adrenal suppression postnatally if maternal use in third trimester. |
| Fertility Effects | Tazarotene may impair fertility in animal studies. Halobetasol propionate may affect menstrual cycle. Impact on human fertility unknown. |
| Food/Dietary |
| No clinically significant food interactions have been reported. However, patients should avoid consuming foods that may increase photosensitivity (e.g., celery, figs, citrus) if significant UV exposure is anticipated. |
| Clinical Pearls | Combination product containing a super-high-potency corticosteroid (halobetasol propionate 0.01%) and a topical retinoid (tazarotene 0.045%). Approved for plaque psoriasis in adults. Apply once daily to affected areas only; not for use on face, groin, axillae, or intertriginous areas. Limit treatment to 8 weeks due to corticosteroid adverse effects. Avoid concomitant use of other topical corticosteroids. Concomitant use of photosensitizing agents (e.g., tetracyclines, fluoroquinolones, thiazides, sulfonamides, phenothiazines) may increase phototoxicity. Use with caution in patients with a history of skin cancer. |
| Patient Advice | Apply a thin layer once daily to psoriasis plaques only, avoiding healthy skin. · Wash hands after application unless treating the hands. · Do not use on face, underarms, or groin area. · Avoid sun exposure, tanning beds, and phototherapy during treatment. · Use sunscreen and wear protective clothing if going outdoors. · Do not use for longer than 8 weeks. · Discontinue use and inform doctor if severe skin irritation, blistering, or infection occurs. · Not for use in children under 18 years. · Temporary stinging or burning may occur upon application. · Inform your doctor of all other medications, especially photosensitizing drugs. |